Substrate reduction therapy in mouse models of the glycosphingolipidoses
about
Less Is More: Substrate Reduction Therapy for Lysosomal Storage DisordersIminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff diseaseSubstrate reduction therapy: clinical evaluation in type 1 Gaucher disease.Gaucher disease and the clinical experience with substrate reduction therapy.[Globosides as key players in the pathophysiology of Shiga toxin-associated acute kidney failure and Fabry disease].Development of targeted therapies for Parkinson's disease and related synucleinopathiesDepletion of globosides and isoglobosides fully reverts the morphologic phenotype of Fabry diseaseSmall-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases.Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.Neurobiology and cellular pathogenesis of glycolipid storage diseases.Biochemistry of glycosphingolipid storage disorders: implications for therapeutic interventionFuture perspectives for glycolipid research in medicine.A historical perspective of the glycosphingolipids and sphingolipidoses.Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice.A systematic investigation of iminosugar click clusters as pharmacological chaperones for the treatment of Gaucher disease.Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice.
P2860
Q26744230-66FEA160-F8EC-4DE1-B3E9-9D46BA691F2BQ28478879-C3434AE9-4BD3-4DF3-9EA9-3F4564FF1258Q33348492-F17C996A-6D8A-4DBA-8890-E3E3471A93ACQ33348495-CA988C0C-08B4-46A0-A882-BD5B884EADA2Q33418419-B4D605C3-C473-4ACA-AD14-F0377F787EF1Q34238616-26B05C74-5021-47B0-B5D5-64C603B34B5AQ34294988-DFBDADBB-DA33-4AE0-929C-81E34066016AQ34534466-8485B435-FEE6-4FC6-BDBA-B49CC69EF0DDQ34557737-7BE93E10-D473-4B84-91BE-012DF230159EQ34584825-AB3EA517-A631-4A57-A43A-E96DD61F1728Q34793236-A2EE1338-C281-4613-A355-D396C85E265EQ35153227-3DE4A775-7464-456F-814A-38FC06C4BB68Q35153233-35E258D0-91EF-4CF8-B4CB-51D2098E1331Q35153243-CE259B58-C3B2-4C0A-A75C-CB857CF395B4Q35213537-C3E8156B-D268-4FE1-AFBE-478C691C3DC3Q45248629-26F46D71-EE0D-4303-B77A-515DD05E94CAQ45716125-90790E6D-FB1A-4941-9E67-5B4B7696E334Q48639806-CEEE6288-DD88-4622-B29C-C821D03ACE9A
P2860
Substrate reduction therapy in mouse models of the glycosphingolipidoses
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Substrate reduction therapy in mouse models of the glycosphingolipidoses
@ast
Substrate reduction therapy in mouse models of the glycosphingolipidoses
@en
type
label
Substrate reduction therapy in mouse models of the glycosphingolipidoses
@ast
Substrate reduction therapy in mouse models of the glycosphingolipidoses
@en
prefLabel
Substrate reduction therapy in mouse models of the glycosphingolipidoses
@ast
Substrate reduction therapy in mouse models of the glycosphingolipidoses
@en
P2093
P2860
P356
P1476
Substrate reduction therapy in mouse models of the glycosphingolipidoses
@en
P2093
Mylvaganam Jeyakumar
Raymond A Dwek
Tanya Heare
Terry D Butters
Ulrika Andersson
P2860
P304
P356
10.1098/RSTB.2003.1279
P407
P577
2003-05-01T00:00:00Z